Forbion Attracts New Investors Closing IV Fund At €360M

European life science companies can expect to get access to almost €290m from Forbion as the EU-based venture capitalist closes its fourth fund at an oversubscribed €360m.

Forbion, a leading European life science venture capital firm, today announced the final close of its new flagship fund, Forbion IV, at €360m in capital commitments, significantly above its original target of €250m. New investors include UK-based Pantheon, Dutch institutions ASR Insurances and the TNO Pension Fund, Nordic investors Formuesforvaltning and KLP, and some undisclosed North American institutional investors. Existing limited partners (LPs) European Investment Fund and development bank KfW also returned as backers of the new fund.

Forbion IV, like its predecessor fund, Forbion III, will primarily focus on biopharma opportunities in the EU including the UK,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

In Brief: Sanofi Cements Support For Adagene

 
• By 

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

Stock Watch: Syncona’s Wild Ride Exposes Suspect Strategies

 
• By 

A track record of positive portfolio performance is described as an investment management skill. Taking difficult divestment decisions early, in challenging markets and outperforming benchmarks, are hallmarks of this skill. Syncona and Woodford Patient Capital offer useful case studies.

More from Business

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

In Brief: Sanofi Cements Support For Adagene

 
• By 

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.